特朗普政府计划使用最惠国定价模式降低药品价格, Trump administration plans to lower drug prices using the Most Favored Nation pricing model, sparking debate.

特朗普政府的目标是通过最惠国定价模式降低美国药物价格,将药物成本定在人均国内生产总值类似的经合组织国家的最低价格。 The Trump administration aims to lower U.S. drug prices through the Most Favored Nation (MFN) pricing model, setting drug costs to the lowest price in OECD countries with similar GDP per capita. 批评者担心这会扼杀美国的制药创新和治疗机会。 Critics worry this could stifle U.S. pharmaceutical innovation and access to treatments. 尽管声称30%至80%的成本降低,但专家们提醒说,这一过程可能不会如此迅速或有效,并着重指出美国保健系统效率低下和药房福利管理人员在定价方面的作用等问题。 Despite claims of 30% to 80% cost reductions, experts caution the process may not be as swift or effective, highlighting issues like inefficiencies in the U.S. healthcare system and the role of Pharmacy Benefit Managers in pricing.